Chemistry:ET-02
ET-02, also known as RS-5441, is a drug which is under development for the treatment of alopecia and hair disorders.[1][2][3] It is taken orally or topical, with both routes being developed.[1] The drug's exact mechanism of action has not yet been disclosed.[1] In any case, it is said to target and restore hair follicle stem cells (HFSCs).[3] ET-02 was originated by Renascience and is now under development by Eirion Therapeutics.[3][1][2] As of July 2025, it is in phase 1 clinical trials for alopecia and no recent development has been reported for hair disorders.[1][2] The drug was reported to promote significant hair growth after 4 weeks of treatment in humans in a phase 1 trial and to do so more rapidly than minoxidil.[3][1] As with its mechanism of action, the chemical structure of ET-02 does not yet appear to have been disclosed.[1]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "RS 5441". 28 July 2025. https://adisinsight.springer.com/drugs/800062839.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on ET-02(Eirion Therapeutics) with Synapse". 20 September 2025. https://synapse.patsnap.com/drug/5a3d869c18da43fca41deeec996506df.
- ↑ 3.0 3.1 3.2 3.3 "The Unprecedented Phase 1 Results of ET-02 for the Treatment of Androgenic Alopecia". 14 January 2025. https://www.dermatologytimes.com/view/the-unprecedented-phase-1-results-of-et-02-for-the-treatment-of-androgenic-alopecia.
 |  |
